Sign in
CompletedPhase 1

Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001

Key facts

Who runs it
Everest Medicines (China) Co.,Ltd.
Where
China19 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 1
People taking part
31 people enrolled
Started
15 May 2023
Ended
27 Jul 2026
Type of study
Interventional, 2 groups
Treatments tested
  • EVER001
Record updated
15 September 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Having clinical diagnosis of primary membranous nephropathy, as verified by biopsy
  • Have positive anti-PLA2R autoantibody test results > 20 relative units (RU)/ml
  • During screening at least one testing of proteinuria must be >3.5 g/24h
  • Have nephrotic range proteinuria for at least 8 weeks prior to Day 1 and no improvement (<50% reduction) despite supportive therapy of ACE inhibitor or ARB unless contraindicated, for patients who have two tests of proteinuria during screening ≥8.0g/24h, the duration of nephrotic range proteinuria for at least 8 weeks is not required

Who cannot take part

  • Have received: B-cell targeted therapy except rituximab at any time;Rituximab and the biosimilars within 2 years (participants with rituximab treatment between 1 and 2 years prior to Day 1 are eligible if there is documented evidence of B-cell repopulation to >90% of Lower Limits of Normal Range.); Cyclophosphamide or Chlorambucil within 180 days;other immunosuppressive/immunomodulatory agents within 90 days;greater than 30mg/day prednisone or equivalence within 30 days
  • Non-primary membranous nephropathy or other condition affecting the kidney
  • Uncontrolled hypertension
  • Acute or chronic infection,including positivity of tuberculosis infection test
  • Positive serology for TP,HIV, HBV, or HCV
  • eGFR at screening < 45 mL/min/1.73m2 or kidney function not stable
  • Serum albumin level at screening # 25g/l
  • Lab testing abnormality as: WBC< 3000/mm³, Lymphocyte < 1000/ mm³, neutrophil <1500/mm³, Hb < 80g/L, Platelet count <100×10e9/ L, Prothrombin time>1.5×ULN, Activated partial thromboplastin time ≥1.5×ULN, Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≥ 1.5×ULN, alkaline phosphatase and bilirubin >1.5×ULN
  • Judged by the investigator that the participant is unlikely to comply with study procedures, restrictions, and requirements

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

EVER001 is a highly selective, oral, reversable, covalent Bruton tyrosine kinase (BTK) inhibitor with high selectivity over other kinases, which is being developed to treat proteinuric glomerular diseases.

Read full original descriptionShow less

The overall aim of the study is to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of EVER001 in subjects with selected proteinuric glomerular diseases. The first targeted disease is primary membranous nephropathy.

The 2 groups in the trial

  • EVER001 100mgTreatment being tested

    EVER001 100mg QD for 4 weeks, followed by EVER001 100mg BID for 32 weeks.

    Treatment: EVER001

  • EVER001 200mgTreatment being tested

    EVER001 200mg BID for 36 weeks.

    Treatment: EVER001

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 1b/2 Study To Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001 In Participants With Selected Proteinuric Glomerular Diseases
Record updated
15 September 2026